Preliminary results show sales boost for Biodesix
LOUISVILLE — Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, reported its preliminary, unaudited revenue results this week for the fourth quarter and full 2024 fiscal year, both of which show improvement.
For the fourth quarter of last year, Biodesix reported sales of $20.4 million, up 39% compared with the same period in 2023. The company posted full-year sales of $71.3 million, up 45% year over year.
“Biodesix capped off a strong fourth quarter and 2024, successfully delivering on our three key initiatives. We grew revenue for both our Lung Diagnostics tests and our Biopharma Services, implemented operational efficiencies, and made progress on our path to profitability through our cost-disciplined approach,” Biodesix CEO Scott Hutton said in a prepared statement.
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, reported its preliminary, unaudited revenue results this week for the fourth quarter and full 2024 fiscal year, both of which show improvement.
Related Posts
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics has clarified its relationship with a clinical researcher who recently received a warning…
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
VitriVax Inc., a Boulder company that is developing vaccine technology, said this week that it…